Ellevest, Inc. Arvinas, Inc. Transaction History

Ellevest, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$26.15 - $37.26 $1,072 - $1,527	41 Added 1025.0%	45 $1,000
Q4 2022 Feb 03, 2023	SELL	$32.47 - $57.24 $714 - $1,259	-22 Reduced 84.62%	4 $0
Q3 2022 Nov 02, 2022	BUY	$41.87 - $57.99 $753 - $1,043	18 Added 225.0%	26 $1,000
Q2 2022 Jul 18, 2022	SELL	$36.01 - $74.24 $324 - $668	-9 Reduced 52.94%	8 $0
Q1 2022 Apr 19, 2022	BUY	$60.27 - $81.57 $1,024 - $1,386	17 New	17 $1,000
Q4 2021 Jan 24, 2022	SELL	$65.85 - $96.21 $395 - $577	-6 Closed	0 $0
Q3 2021 Oct 19, 2021	BUY	$73.2 - $107.87 $439 - $647	6 New	6 $0

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.